TMED3
geneOn this page
Also known as p24Bp24gamma4p24g4
Summary
TMED3 (transmembrane p24 trafficking protein 3, HGNC:28889) is a protein-coding gene on chromosome 15q25.1, encoding Transmembrane emp24 domain-containing protein 3 (Q9Y3Q3). Potential role in vesicular protein trafficking, mainly in the early secretory pathway.
Predicted to be involved in Golgi organization; endoplasmic reticulum to Golgi vesicle-mediated transport; and intracellular protein transport. Located in Golgi apparatus; endoplasmic reticulum; and endoplasmic reticulum-Golgi intermediate compartment.
Source: NCBI Gene 23423 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 38 total
- MANE Select transcript:
NM_007364
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:28889 |
| Approved symbol | TMED3 |
| Name | transmembrane p24 trafficking protein 3 |
| Location | 15q25.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | p24B, p24gamma4, p24g4 |
| Ensembl gene | ENSG00000166557 |
| Ensembl biotype | protein_coding |
| OMIM | 620437 |
| Entrez | 23423 |
Gene structure
Transcript identifiers
Ensembl transcripts: 7 — 5 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined
ENST00000299705, ENST00000424155, ENST00000536821, ENST00000543455, ENST00000558562, ENST00000896882, ENST00000964020
RefSeq mRNA: 4 — MANE Select: NM_007364
NM_001301203, NM_001330376, NM_001363735, NM_007364
CCDS: CCDS10310, CCDS73768, CCDS81914, CCDS86480
Canonical transcript exons
ENST00000299705 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001104161 | 79313757 | 79314005 |
| ENSE00001104166 | 79321978 | 79322840 |
| ENSE00001895269 | 79311112 | 79311417 |
Expression profiles
Bgee: expression breadth ubiquitous, 280 present calls, max score 99.38.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 86.3459 / max 970.0310, expressed in 1820 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 147944 | 47.4542 | 1810 |
| 147943 | 32.4436 | 1811 |
| 147945 | 5.8444 | 1605 |
| 207607 | 0.6037 | 345 |
Top tissues by expression
297 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| parotid gland | UBERON:0001831 | 99.38 | gold quality |
| body of pancreas | UBERON:0001150 | 98.64 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 98.39 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 98.36 | gold quality |
| minor salivary gland | UBERON:0001830 | 98.11 | gold quality |
| endometrium epithelium | UBERON:0004811 | 98.01 | gold quality |
| stromal cell of endometrium | CL:0002255 | 97.97 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 97.97 | gold quality |
| mouth mucosa | UBERON:0003729 | 97.78 | gold quality |
| esophagus mucosa | UBERON:0002469 | 97.61 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 97.59 | gold quality |
| skin of leg | UBERON:0001511 | 97.42 | gold quality |
| skin of abdomen | UBERON:0001416 | 97.28 | gold quality |
| adenohypophysis | UBERON:0002196 | 97.26 | gold quality |
| islet of Langerhans | UBERON:0000006 | 97.13 | gold quality |
| pancreas | UBERON:0001264 | 97.05 | gold quality |
| pituitary gland | UBERON:0000007 | 96.98 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 96.93 | gold quality |
| zone of skin | UBERON:0000014 | 96.71 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 96.60 | gold quality |
| gingival epithelium | UBERON:0001949 | 96.60 | gold quality |
| gingiva | UBERON:0001828 | 96.58 | gold quality |
| epithelium of esophagus | UBERON:0001976 | 96.58 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 96.57 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 96.32 | gold quality |
| nasal cavity mucosa | UBERON:0001826 | 96.31 | gold quality |
| type B pancreatic cell | CL:0000169 | 96.12 | gold quality |
| thyroid gland | UBERON:0002046 | 96.07 | gold quality |
| oral cavity | UBERON:0000167 | 95.79 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 95.79 | gold quality |
Single-cell (SCXA)
Detected in 4 experiment(s), a significant marker in 4.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-5061 | yes | 27.32 |
| E-HCAD-31 | yes | 21.95 |
| E-CURD-112 | yes | 7.10 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
14 targeting TMED3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-188-3P | 100.00 | 68.76 | 1240 |
| HSA-MIR-12124 | 99.68 | 69.17 | 2700 |
| HSA-MIR-186-3P | 99.51 | 66.24 | 1685 |
| HSA-MIR-6727-3P | 99.49 | 65.92 | 1333 |
| HSA-MIR-8064 | 99.45 | 66.92 | 875 |
| HSA-MIR-449B-3P | 99.20 | 67.24 | 1047 |
| HSA-MIR-6852-5P | 99.17 | 66.69 | 2073 |
| HSA-MIR-670-3P | 99.03 | 68.88 | 2404 |
| HSA-MIR-5001-3P | 98.91 | 67.28 | 1394 |
| HSA-MIR-1178-3P | 98.57 | 67.09 | 890 |
| HSA-MIR-216B-3P | 98.55 | 67.19 | 1223 |
| HSA-MIR-3920 | 97.75 | 69.02 | 1168 |
| HSA-MIR-4253 | 97.48 | 65.11 | 692 |
| HSA-MIR-6862-5P | 97.48 | 64.84 | 713 |
Literature-anchored findings (GeneRIF, showing 9)
- AIM1, ERGIC1, and TPX2 were shown to be highly expressed especially in prostate cancer tissues, and high mRNA expression of ERGIC1 and TMED3 associated with AR and ERG oncogene expression (PMID:22761906)
- This genome-wide screen has identified two novel metastatic suppressors: TMED3 and SOX12, the knockdown of which increases metastatic growth after direct seeding. (PMID:24920608)
- Study demonstrates that transmembrane p24 trafficking protein 3 (TMED3) promotes hepatocellular carcinoma (HCC) metastasis and is a potential prognostic biomarker in hepatocellular carcinoma. Study propose that TMED3 promotes HCC metastasis through IL-11/STAT3 signaling. (PMID:27901021)
- Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells. (PMID:33760171)
- TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR. (PMID:34429402)
- TMED3 exerts a protumor function in non-small cell lung cancer by enhancing the Wnt/beta-catenin pathway via regulation of AKT. (PMID:34758370)
- Trafficking protein TMED3 promotes esophageal squamous cell carcinoma. (PMID:35358714)
- Analysis and Validation of TMED3 correlates with poor prognosis and tumor immune infiltration of glioma. (PMID:35951089)
- TMED3 stabilizes SMAD2 by counteracting NEDD4-mediated ubiquitination to promote ovarian cancer. (PMID:38411267)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | tmed3 | ENSDARG00000028816 |
| mus_musculus | Tmed3 | ENSMUSG00000032353 |
| rattus_norvegicus | Tmed3 | ENSRNOG00000013889 |
| drosophila_melanogaster | p24-1 | FBGN0030341 |
| caenorhabditis_elegans | WBGENE00011606 |
Paralogs (8): TMED2 (ENSG00000086598), TMED1 (ENSG00000099203), TMED5 (ENSG00000117500), TMED7 (ENSG00000134970), TMED6 (ENSG00000157315), TMED4 (ENSG00000158604), TMED10 (ENSG00000170348), TMED9 (ENSG00000184840)
Protein
Protein identifiers
Transmembrane emp24 domain-containing protein 3 — Q9Y3Q3 (reviewed: Q9Y3Q3)
Alternative names: Membrane protein p24B, p24 family protein gamma-4, p26
All UniProt accessions (4): A0A140VKD1, Q9Y3Q3, F5H4M7, G3V1J9
UniProt curated annotations — full annotation on UniProt →
Function. Potential role in vesicular protein trafficking, mainly in the early secretory pathway. Contributes to the coupled localization of TMED2 and TMED10 in the cis-Golgi network.
Subunit / interactions. Monomer in endoplasmic reticulum, endoplasmic reticulum-Golgi intermediate compartment and cis-Golgi network. Interacts (via C-terminus) with COPG1; the interaction involves dimeric TMED3; however, there are conflicting reports on the interaction. Interacts with GORASP1 and GORASP2.
Subcellular location. Endoplasmic reticulum-Golgi intermediate compartment membrane. Golgi apparatus. cis-Golgi network membrane. Golgi stack membrane. Endoplasmic reticulum membrane. Cytoplasmic vesicle. COPI-coated vesicle membrane.
Similarity. Belongs to the EMP24/GP25L family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9Y3Q3-1 | 1 | yes |
| Q9Y3Q3-2 | 2 |
RefSeq proteins (4): NP_001288132, NP_001317305, NP_001350664, NP_031390* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR009038 | GOLD_dom | Domain |
| IPR015720 | Emp24-like | Family |
| IPR036598 | GOLD_dom_sf | Homologous_superfamily |
Pfam: PF01105
UniProt features (10 total): topological domain 2, short sequence motif 2, signal peptide 1, chain 1, transmembrane region 1, domain 1, splice variant 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9Y3Q3-F1 | 88.51 | 0.69 |
Function
Pathways and Gene Ontology
Reactome pathways
2 pathways
| ID | Pathway |
|---|---|
| R-HSA-6807878 | COPI-mediated anterograde transport |
| R-HSA-6811434 | COPI-dependent Golgi-to-ER retrograde traffic |
MSigDB gene sets: 211 (showing top):
GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, MODULE_52, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, MODULE_255, ENK_UV_RESPONSE_KERATINOCYTE_UP, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, MODULE_317, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, GOBP_ENDOPLASMIC_RETICULUM_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT, GOCC_COATED_VESICLE, GOCC_GOLGI_ASSOCIATED_VESICLE, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, GOCC_VESICLE_COAT
GO Biological Process (4): intracellular protein transport (GO:0006886), endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888), Golgi organization (GO:0007030), protein transport (GO:0015031)
GO Molecular Function (0):
GO Cellular Component (13): Golgi membrane (GO:0000139), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), endoplasmic reticulum-Golgi intermediate compartment (GO:0005793), Golgi apparatus (GO:0005794), COPI vesicle coat (GO:0030126), transport vesicle (GO:0030133), COPII-coated ER to Golgi transport vesicle (GO:0030134), Golgi cisterna membrane (GO:0032580), endoplasmic reticulum-Golgi intermediate compartment membrane (GO:0033116), membrane (GO:0016020), COPI-coated vesicle membrane (GO:0030663), cytoplasmic vesicle (GO:0031410)
Reactome top-level categories
Rollup of top-2 pathways:
| Category | Pathways |
|---|---|
| ER to Golgi Anterograde Transport | 1 |
| Golgi-to-ER retrograde transport | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cytoplasm | 5 |
| endomembrane system | 3 |
| intracellular membrane-bounded organelle | 3 |
| intracellular protein localization | 2 |
| intracellular transport | 2 |
| Golgi apparatus | 2 |
| bounding membrane of organelle | 2 |
| organelle membrane | 2 |
| protein transport | 1 |
| intercellular transport | 1 |
| Golgi vesicle transport | 1 |
| organelle organization | 1 |
| endomembrane system organization | 1 |
| transport | 1 |
| establishment of protein localization | 1 |
| nuclear outer membrane-endoplasmic reticulum membrane network | 1 |
| endoplasmic reticulum subcompartment | 1 |
| vesicle coat | 1 |
| COPI-coated vesicle membrane | 1 |
| cytoplasmic vesicle | 1 |
| coated vesicle | 1 |
| Golgi cisterna | 1 |
| endoplasmic reticulum-Golgi intermediate compartment | 1 |
| cellular anatomical structure | 1 |
| COPI-coated vesicle | 1 |
| Golgi-associated vesicle membrane | 1 |
| coated vesicle membrane | 1 |
| intracellular vesicle | 1 |
Protein interactions and networks
STRING
1308 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TMED3 | TMED10 | P49755 | 603 |
| TMED3 | AKAP12 | Q02952 | 486 |
| TMED3 | TMED6 | Q8WW62 | 478 |
| TMED3 | CNIH4 | Q9P003 | 463 |
| TMED3 | CCT3 | P49368 | 424 |
| TMED3 | BABAM1 | Q9NWV8 | 395 |
| TMED3 | VAV3 | Q9UKW4 | 391 |
| TMED3 | GORASP1 | Q9BQQ3 | 384 |
| TMED3 | SMIM13 | P0DJ93 | 374 |
| TMED3 | TMED9 | Q9BVK6 | 356 |
| TMED3 | TMED8 | Q6PL24 | 350 |
| TMED3 | PHKB | Q93100 | 349 |
| TMED3 | RBM26 | Q5T8P6 | 345 |
| TMED3 | SPRYD4 | Q8WW59 | 343 |
| TMED3 | GUCA2A | Q02747 | 341 |
IntAct
32 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| TMED10 | TMED1 | psi-mi:“MI:0914”(association) | 0.730 |
| TMED9 | TMED10 | psi-mi:“MI:0914”(association) | 0.730 |
| TMED2 | ATP9A | psi-mi:“MI:0914”(association) | 0.640 |
| TMED3 | HS1BP3 | psi-mi:“MI:0914”(association) | 0.530 |
| SEC23A | TMED3 | psi-mi:“MI:0915”(physical association) | 0.400 |
| Tmed10 | TARS3 | psi-mi:“MI:0914”(association) | 0.350 |
| Tmed2 | psi-mi:“MI:0914”(association) | 0.350 | |
| MYBBP1A | TMED10 | psi-mi:“MI:0914”(association) | 0.350 |
| PGRMC1 | NBAS | psi-mi:“MI:0914”(association) | 0.350 |
| PSMB10 | DDX46 | psi-mi:“MI:0914”(association) | 0.350 |
| TMED10 | PGRMC1 | psi-mi:“MI:0914”(association) | 0.350 |
| TCTN2 | TMEM131L | psi-mi:“MI:0914”(association) | 0.350 |
| SPPL2B | GPR89A | psi-mi:“MI:0914”(association) | 0.350 |
| CHST8 | NDUFS8 | psi-mi:“MI:0914”(association) | 0.350 |
| SPPL2B | HAS3 | psi-mi:“MI:0914”(association) | 0.350 |
| TMED2 | SMPD2 | psi-mi:“MI:0914”(association) | 0.350 |
| TMED10 | CYC1 | psi-mi:“MI:0914”(association) | 0.350 |
| TMED2 | ATP12A | psi-mi:“MI:0914”(association) | 0.350 |
| CLDND1 | PPL | psi-mi:“MI:0914”(association) | 0.350 |
| SAAL1 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| SPPL2B | POC1B-GALNT4 | psi-mi:“MI:0914”(association) | 0.350 |
| TMED10 | TMED7-TICAM2 | psi-mi:“MI:0914”(association) | 0.350 |
| TMED2 | psi-mi:“MI:0914”(association) | 0.350 | |
| MFSD5 | ILVBL | psi-mi:“MI:0914”(association) | 0.350 |
| SLC30A10 | GOLIM4 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC30A7 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (56): TMED3 (Affinity Capture-RNA), TMED3 (Affinity Capture-RNA), TMED3 (Affinity Capture-MS), CCPG1 (Affinity Capture-MS), TMED4 (Affinity Capture-MS), OSBPL8 (Affinity Capture-MS), TMED2 (Affinity Capture-MS), HS1BP3 (Affinity Capture-MS), BLZF1 (Affinity Capture-MS), TMEM30A (Affinity Capture-MS), KIAA1715 (Affinity Capture-MS), TMED10 (Co-fractionation), TMED3 (Co-fractionation), TMED3 (Affinity Capture-MS), TMED3 (Affinity Capture-MS)
ESM2 similar proteins: A0A0G2KTI4, A0A7U2QYM2, A1CKN5, A5AAA1, A7SXK3, A8N0V8, B0CPJ0, B0WEV5, B2VVF0, F4JJJ3, O04015, O04226, O17528, P32296, P55014, P55015, P55016, P58421, P91926, Q0CNR4, Q13621, Q28BQ6, Q29N38, Q2KJ84, Q4HY20, Q5B5L5, Q5B971, Q5R809, Q69SA9, Q6AXN3, Q6AY25, Q78IS1, Q7QG73, Q870U4, Q948T9, Q949M9, Q94BV7, Q9CXE7, Q9DEB5, Q9HEK4
Diamond homologs: A7SXK3, D3ZTX0, O17528, P32803, P49020, Q15363, Q3T133, Q54BN0, Q5I0E7, Q63524, Q6AY25, Q6BTC2, Q769F9, Q78IS1, Q7Z7H5, Q8R1V4, Q99KF1, Q9P7I9, Q9R0Q3, Q9Y3B3, Q9Y3Q3, O13770, Q13445, Q28BQ6, Q2KJ84, Q2TBK5, Q3V009, Q5BK85, Q5R7E6, Q5R809, Q6AXN3, Q9BVK6, Q9CXE7, Q9Y3A6, P39704, Q12450, Q05359, Q4P958, B3MTS8, B3NZM5
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 40 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| intracellular protein transport | 5 | 10.4× | 3e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
38 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 29 |
| Likely benign | 3 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
601 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 15:79311418:G:A | donor_loss | 1.0000 |
| 15:79313755:A:AG | acceptor_gain | 1.0000 |
| 15:79313756:G:GG | acceptor_gain | 1.0000 |
| 15:79313756:GGTC:G | acceptor_gain | 1.0000 |
| 15:79314002:CCAGG:C | donor_loss | 1.0000 |
| 15:79314004:AGGTG:A | donor_loss | 1.0000 |
| 15:79314006:G:GA | donor_loss | 1.0000 |
| 15:79314007:T:A | donor_loss | 1.0000 |
| 15:79311379:G:GT | donor_gain | 0.9900 |
| 15:79311383:TG:T | donor_gain | 0.9900 |
| 15:79311384:GG:G | donor_gain | 0.9900 |
| 15:79311418:G:GG | donor_gain | 0.9900 |
| 15:79313747:T:TA | acceptor_gain | 0.9900 |
| 15:79313748:G:A | acceptor_gain | 0.9900 |
| 15:79313755:AG:A | acceptor_gain | 0.9900 |
| 15:79313756:GG:G | acceptor_gain | 0.9900 |
| 15:79313756:GGT:G | acceptor_gain | 0.9900 |
| 15:79313756:GGTCA:G | acceptor_gain | 0.9900 |
| 15:79313874:G:GT | donor_gain | 0.9900 |
| 15:79314006:G:GG | donor_gain | 0.9900 |
| 15:79321971:T:TA | acceptor_gain | 0.9900 |
| 15:79321972:GCCCA:G | acceptor_loss | 0.9900 |
| 15:79321973:CCCAG:C | acceptor_loss | 0.9900 |
| 15:79321974:CCAG:C | acceptor_loss | 0.9900 |
| 15:79321976:A:AC | acceptor_loss | 0.9900 |
| 15:79321976:A:AG | acceptor_gain | 0.9900 |
| 15:79321976:AGAT:A | acceptor_gain | 0.9900 |
| 15:79321976:AGATG:A | acceptor_gain | 0.9900 |
| 15:79321977:G:GG | acceptor_gain | 0.9900 |
| 15:79321977:GAT:G | acceptor_gain | 0.9900 |
AlphaMissense
1421 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 15:79313924:G:C | K112N | 0.999 |
| 15:79313924:G:T | K112N | 0.999 |
| 15:79313929:T:A | V114D | 0.999 |
| 15:79313893:T:C | F102S | 0.998 |
| 15:79313899:A:T | N104I | 0.998 |
| 15:79313900:T:A | N104K | 0.998 |
| 15:79313900:T:G | N104K | 0.998 |
| 15:79313782:T:A | V65D | 0.997 |
| 15:79313904:T:C | F106L | 0.997 |
| 15:79313906:T:A | F106L | 0.997 |
| 15:79313906:T:G | F106L | 0.997 |
| 15:79313922:A:G | K112E | 0.997 |
| 15:79313923:A:T | K112M | 0.997 |
| 15:79322012:T:C | L151P | 0.997 |
| 15:79322140:A:C | S194R | 0.997 |
| 15:79322142:C:A | S194R | 0.997 |
| 15:79322142:C:G | S194R | 0.997 |
| 15:79313767:G:A | G60E | 0.995 |
| 15:79313898:A:T | N104Y | 0.995 |
| 15:79322045:G:C | R162P | 0.995 |
| 15:79322066:G:C | R169P | 0.995 |
| 15:79313923:A:C | K112T | 0.994 |
| 15:79322056:G:C | A166P | 0.994 |
| 15:79311371:T:C | F41S | 0.993 |
| 15:79313892:T:C | F102L | 0.993 |
| 15:79313894:C:A | F102L | 0.993 |
| 15:79313894:C:G | F102L | 0.993 |
| 15:79313908:C:T | S107F | 0.993 |
| 15:79313922:A:C | K112Q | 0.993 |
| 15:79322074:G:C | A172P | 0.993 |
dbSNP variants (sampled 300 via entrez): RS1000018760 (15:79396404 C>T), RS1000027917 (15:79354747 G>T), RS1000039156 (15:79354904 G>A), RS1000077196 (15:79383553 G>A), RS1000099393 (15:79386299 A>G), RS1000131508 (15:79377155 T>A), RS1000210279 (15:79379205 T>A), RS1000227754 (15:79337013 C>T), RS1000302577 (15:79367194 A>G,T), RS1000414632 (15:79354838 GC>G,GCC), RS1000531739 (15:79381799 C>G), RS1000544621 (15:79320085 A>G), RS1000566162 (15:79340123 G>A), RS1000622715 (15:79315899 G>A), RS1000644746 (15:79356425 A>G)
Disease associations
OMIM: gene MIM:620437 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004735_29 | Epstein-Barr virus copy number in lymphoblastoid cell lines | 3.000000e-06 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
21 total (human), top 21 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Cisplatin | affects expression, affects response to substance | 2 |
| triphenyl phosphate | affects expression | 1 |
| sodium arsenite | decreases expression | 1 |
| tebuconazole | decreases expression | 1 |
| jinfukang | increases expression | 1 |
| XAV939 | decreases reaction, increases expression | 1 |
| MK 2206 | decreases reaction, increases expression, increases phosphorylation | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| Decitabine | affects expression | 1 |
| Azacitidine | increases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Cadmium | increases expression, increases abundance | 1 |
| Doxorubicin | increases expression | 1 |
| Hydralazine | increases expression, affects cotreatment | 1 |
| Ivermectin | decreases expression | 1 |
| Lead | affects expression | 1 |
| Smoke | decreases expression | 1 |
| Tobacco Smoke Pollution | increases expression | 1 |
| Valproic Acid | increases expression, affects cotreatment | 1 |
| Cadmium Chloride | increases expression, increases abundance | 1 |
| Copper Sulfate | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): Epstein-Barr virus infection